Capital Analysts LLC Has $9.40 Million Stake in Zoetis Inc. (NYSE:ZTS)

Capital Analysts LLC boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 57,713 shares of the company's stock after buying an additional 3,025 shares during the quarter. Capital Analysts LLC's holdings in Zoetis were worth $9,403,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ZTS. Mission Wealth Management LP lifted its stake in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares during the period. VeraBank N.A. lifted its position in shares of Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after acquiring an additional 62 shares during the period. HUB Investment Partners LLC grew its holdings in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC raised its stake in shares of Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Coppell Advisory Solutions LLC lifted its position in Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZTS. Piper Sandler upped their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $214.40.

Zoetis Price Performance

Shares of ZTS stock traded down $0.09 during trading hours on Thursday, reaching $156.31. 803,437 shares of the company were exchanged, compared to its average volume of 2,478,322. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock's fifty day moving average is $158.73 and its two-hundred day moving average is $167.90. The company has a market cap of $69.74 billion, a price-to-earnings ratio of 28.57, a P/E/G ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.28%. Zoetis's dividend payout ratio is currently 36.56%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock worth $312,254. Company insiders own 0.16% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.